Chinese drug R&D platform Yaoyanshe pockets $86m in Series C+, D

Chinese drug R&D platform Yaoyanshe pockets $86m in Series C+, D

Source: Volodymyr Hryshchenko/Unsplash

Yaoyanshe, a Chinese technology platform that offers novel drug research and development services, has garnered over 600 million yuan ($86 million) across two rounds in the past eight months.

The company enables pharma players to reduce their drug development cycles and costs.

Bring stories like this into your inbox every day.

Sign up for our newsletter - The Daily Brief
Subscribe to Newsletter